| [1] |
Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022 [J]. CA Cancer J Clin, 2022, 72(5): 409-436.
|
| [2] |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016 [J]. JNCC, 2022, 2(1): 1-9.
|
| [3] |
李恒平, 张矛, 王向荣, 等. 转移性前列腺癌治疗药物的最新进展[J]. 中国男科学杂志, 2022, 36(4): 101-107.
|
| [4] |
冯涛. 前列腺癌联合免疫治疗的研究进展[J]. 国际泌尿系统杂志, 2021, 41(1): 171-5.
|
| [5] |
王岩, 薛蔚. 前列腺癌肿瘤免疫微环境的研究进展[J]. 国际泌尿系统杂志, 2022, 42(1): 127-130.
|
| [6] |
曾进, 陈忠. 前列腺癌肿瘤疫苗免疫治疗研究进展[J]. 现代泌尿生殖肿瘤杂志, 2016, 8(6): 321-323.
|
| [7] |
何华东, 李昶灸. 免疫检查点抑制剂治疗转移性去势抵抗性前列腺癌的研究进展[J]. 浙江医学, 2021, 43(24): 2613-2618.
|
| [8] |
景文江，陈嘉琦，罗若楠，马武. 宫颈癌患者免疫功能、肠道微生物与放射性肠炎的相关性研究[J].新医学, 2023, 54(9): 676-680.
|
| [9] |
高西壮, 杨永红, 于伟, 等. 调节性细胞死亡在炎症性肠病中的研究进展[J]. 中华炎性肠病杂志, 2023, 7(4): 365-370.
|
| [10] |
Apert C, Galindo-albarran AO, Castan S, et al. IL-2 and IL-15 drive intrathymic development of distinct periphery-seeding CD4(+)Foxp3(+) regulatory T lymphocytes [J]. Front Immunol, 2022, 13: 965303.
|
| [11] |
Oita S, Saito T, Sakamoto A, et al. Frequency and function of circulating regulatory T-cells in biliary atresia [J]. Pediatr Surg Int, 2022, 39(1): 23.
|
| [12] |
Ju M, Fan J, Zou Y, et al. Computational recognition of a regulatory T-cell-specific signature with potential implications in prognosis, immunotherapy, and therapeutic resistance of prostate cancer [J]. Front Immunol, 2022, 13: 807840.
|
| [13] |
Maeda S, Motegi T, Iio A, et al. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer [J]. J Immunother Cancer, 2022, 10(2): e003731.
|
| [14] |
Davidsson S, Carlsson J, Greenberg L, et al. Cutibacterium acnes induces the expression of immunosuppressive genes in macrophages and is associated with an increase of regulatory T-Cells in prostate cancer [J]. Microbiol Spectr, 2021, 9(3): e0149721.
|
| [15] |
Laheurte C, Thiery-vuillemin A, Calcagno F, et al. Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer [J]. Int J Cancer, 2020, 147(4): 1199-1205.
|
| [16] |
章步文,黎钢,叶津津,等.不同分期前列腺癌患者外周血CD4+ CD25+ Foxp3+调节性T细胞的变化及与胰岛素抵抗的相关性[J].中华男科学杂志, 2015, 21(5): 420-423.
|
| [17] |
Bejarano L, Jordao MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment [J]. Cancer Discov, 2021, 11(4): 933-959.
|
| [18] |
Larionova I, Tuguzbaeva G, Ponomaryova A, et al. Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers [J]. Front Oncol, 2020, 10: 566511.
|
| [19] |
Pozzi S, Scomparin A, Ben-shushan D, et al. MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression [J]. JCI Insight, 2022, 7(17): e154804.
|
| [20] |
Wu K, Lin K, Li X, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment [J]. Front Immunol, 2020, 11: 1731.
|
| [21] |
程叶, 蒯晴叶, 张艳, 等. TAM在肿瘤免疫治疗中的研究进展[J/OL]. 肿瘤: 1-11[2023-11-15].
URL
|
| [22] |
夏莹, 张岩, 杨永广, 等. 靶向肿瘤相关巨噬细胞的肿瘤治疗研究进展[J]. 中国免疫学杂志, 2019, 35(11): 1405-1409.
|
| [23] |
胡香萍. 肿瘤相关巨噬细胞在肿瘤中的作用及治疗策略研究[J]. 医学信息, 2022, 35(20): 166-169.
|
| [24] |
Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers [J]. Nat Med, 2015, 21(8): 938-945.
|
| [25] |
Xie T, Fu DJ, Li ZM, et al. CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling [J]. Mol Cancer, 2022, 21(1): 173.
|
| [26] |
Osmulski PA, Cunsolo A, Chen M, et al. Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer [J]. Cancer Res, 2021, 81(15): 4110-4123.
|
| [27] |
Peng Y, Zhao M, Hu Y, et al. Blockade of exosome generation by GW4869 inhibits the education of M2 macrophages in prostate cancer [J]. BMC Immunol, 2022, 23(1): 37.
|
| [28] |
崔维刚, 时会芳, 张敏, 等. 髓源性抑制细胞在肿瘤微环境中作用的研究进展[J]. 中国医药, 2022, 17(10): 1592-1596.
|
| [29] |
Calcinotto A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer [J]. Nature, 2018, 559(7714): 363-369.
|
| [30] |
Koinis F, Xagara A, Chantzara E, et al. Myeloid-derived suppressor cells in prostate cancer: present knowledge and future perspectives [J]. Cells, 2021, 11(1):20.
|
| [31] |
Macias M, Garcia-cortes A, Torres M, et al. Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients [J]. Cytokine, 2021, 141: 155471.
|
| [32] |
Lopez-bujanda ZA, Haffner MC, Chaimowitz MG, et al. Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression [J]. Nat Cancer, 2021, 2(8): 803-818.
|
| [33] |
Gao F, Xu Q, Tang Z, et al. Exosomes derived from myeloid-derived suppressor cells facilitate castration-resistant prostate cancer progression via S100A9/circMID1/miR-506-3p/MID1 [J]. J Transl Med, 2022, 20(1): 346.
|
| [34] |
Jia Q, Wu W, Wang Y, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer [J]. Nat Commun, 2018, 9(1): 5361.
|
| [35] |
姚亚龙, 李金洲, 穆彦熹, 等. 微原纤维相关糖蛋白在实体肿瘤中的研究进展[J]. 现代消化及介入诊疗, 2022, 27(10): 1356-1362.
|
| [36] |
Liu W, Wang MM, Wang M, et al. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer [J]. Medicine (Baltimore), 2023, 102(32): e34611.
|
| [37] |
杨肖莉, 薛桦, 于莹, 等. 肿瘤相关成纤维细胞促癌作用的研究进展[J]. 国际检验医学杂志, 2022, 43(18): 2292-2297.
|
| [38] |
Liao CP, Chen LY, Luethy A, et al. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells [J]. Endocr Relat Cancer, 2017, 24(4): 157-170.
|
| [39] |
Shen T, Li Y, Wang D, et al. YAP1-TEAD1 mediates the perineural invasion of prostate cancer cells induced by cancer-associated fibroblasts [J]. Biochim Biophys Acta Mol Basis Dis, 2022, 1868(12): 166540.
|
| [40] |
Jia D, Zhou Z, Kwon OJ, et al. Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity [J]. Nat Commun, 2022, 13(1): 6828.
|
| [41] |
Ma J, Chen X, Chen Y, et al. Ligustilide inhibits tumor angiogenesis by downregulating VEGFA secretion from cancer-associated fibroblasts in prostate cancer via TLR4 [J]. Cancers (Basel), 2022, 14(10): 2046.
|